ConCallIQ
Go Pro
Home › Cipla › PAT History

Cipla PAT History — Quarter by Quarter

Cipla's pat moved from ₹996 Cr in Q1 FY24 to ₹543 Cr in Q4 FY26, a -45.5% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

PAT by Quarter

QuarterPAT (₹ Cr)YoY Change
Q4 FY26₹543 Cr—
Q3 FY26₹676 Cr—
Q2 FY26₹1,351 Cr—
Q1 FY26₹1,298 Cr+10.2%
Q4 FY25₹1,222 Cr—
Q3 FY25₹1,571 Cr—
Q2 FY25₹1,303 Cr—
Q1 FY25₹1,178 Cr—
Q4 FY24₹939 Cr—
Q3 FY24₹1,049 Cr—
Q2 FY24₹1,131 Cr—
Q1 FY24₹996 Cr—

What management said about pat

G

Q2 FY26 · Generic Revlimid contribution immaterial from Q3 FY26

Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.

G

Q3 FY25 · FY26 top-line growth guidance retained

Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.

G

Q1 FY24 · Advair launch within 12 months via de-risking

Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.